RO5323441 + sorafenib

RO5323441 + sorafenib is an experimental **combination therapy** consisting of RO5323441, a humanized monoclonal antibody targeting **placenta growth factor** (PlGF), and sorafenib, a multikinase small molecule inhibitor. RO5323441 blocks PlGF from activating its receptor, **vascular endothelial growth factor receptor-1 (VEGFR-1)**, thereby inhibiting angiogenesis, while sorafenib inhibits multiple kinases involved in cell proliferation and tumor angiogenesis, including **RAF kinase** and **VEGF receptors**. This combination has been primarily investigated in **hepatocellular carcinoma** and other advanced solid tumors for its potential dual anti-angiogenic and antineoplastic activity[1][2][5][7][9].